![]() |
市場調査レポート
商品コード
1619021
心臓再同期療法の市場規模、シェア、成長分析、製品別、用途別、エンドユーザー別、地域別 - 産業予測、2024~2031年Cardiac Resynchronization Therapy Market Size, Share, Growth Analysis, By Product, By Application (Intraventricular Desynchrony, Interventricular Desynchrony), By End User, By Region - Industry Forecast 2024-2031 |
||||||
|
心臓再同期療法の市場規模、シェア、成長分析、製品別、用途別、エンドユーザー別、地域別 - 産業予測、2024~2031年 |
出版日: 2024年12月18日
発行: SkyQuest
ページ情報: 英文 242 Pages
納期: 3~5営業日
|
心臓再同期療法の世界市場規模は2022年に41億米ドルと評価され、2023年の42億9,000万米ドルから2031年には61億5,000万米ドルに成長し、予測期間(2024~2031年)のCAGRは4.6%で成長する見通しです。
心臓再同期療法市場は、対象疾患の罹患率の上昇、心臓発作の有病率の急増、治療への投資の増加、ヘルスケア支出の増加などを背景に成長する見込みです。さらに、技術の進歩、医療機器の近代化、新興市場への進出、老年人口の増加が市場成長をさらに促進します。しかし、不利な医療制度改革、手術部位感染リスクの高まり、機器の高感度化といった課題は、この成長を抑制する可能性があり、予測期間中に対処すべきハードルとなります。これらの力学を理解することは、市場情勢の進化をナビゲートしようとする利害関係者にとって極めて重要です。
Global Cardiac Resynchronization Therapy Market size was valued at USD 4.1 billion in 2022 and is poised to grow from USD 4.29 billion in 2023 to USD 6.15 billion by 2031, growing at a CAGR of 4.6% during the forecast period (2024-2031).
The cardiac resynchronization therapy market is poised for growth, driven by a rising incidence of target diseases, a surge in heart attack prevalence, increased investment in treatment, and growing healthcare expenditures. Additionally, advancements in technology, modernization of medical equipment, expansion into emerging markets, and a growing geriatric population will further propel market growth. However, challenges such as unfavorable healthcare reforms, heightened risks of surgical site infections, and high sensitivity of devices could restrain this growth, presenting hurdles that need to be addressed during the forecast period. Understanding these dynamics will be crucial for stakeholders looking to navigate the evolving landscape of the cardiac resynchronization therapy market.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cardiac Resynchronization Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cardiac Resynchronization Therapy Market Segmental Analysis
Global Cardiac Resynchronization Therapy Market is segmented by product, application, end user and region. Based on product, the market is segmented into cardiac resynchronization therapy defibrillators and cardiac resynchronization therapy pacemakers. Based on application, the market is segmented into intraventricular desynchrony, interventricular (V-V) desynchrony and atrioventricular (A-V) desynchrony. Based on end user, the market is segmented into hospitals & cardiac centers, ambulatory surgery centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Cardiac Resynchronization Therapy Market
The Global Cardiac Resynchronization Therapy market is significantly driven by the escalating prevalence of cardiovascular diseases, which continue to pose a serious health challenge worldwide. Sudden cardiac death accounts for nearly half of all fatalities linked to cardiovascular conditions, underscoring the urgent need for effective interventions. Despite advancements in treatment options, the incidence of heart diseases and associated risk factors is on the rise, leading to an increased demand for cardiac resynchronization therapy devices. With heart failure being one of the primary causes of mortality globally, the necessity for innovative therapies is more critical than ever, prompting growth in this market.
Restraints in the Global Cardiac Resynchronization Therapy Market
A significant restraint in the Global Cardiac Resynchronization Therapy market is the issue of product recalls, which can affect consumer confidence and market growth. For example, Boston Scientific Corporation initiated a recall of its INGENIO family of pacemakers and CRT-Ps in June 2022, which included models like the ADVANTIO DR EL, INGENIO DR EL, and VITALIO DR EL. These devices were distributed in the U.S. between November 2016 and August 2022, having been manufactured from September 2016 to December 2018, totaling around 48,000 units. The recall was prompted by concerns that the devices could inadvertently enter safety mode, posing risks to patients' well-being.
Market Trends of the Global Cardiac Resynchronization Therapy Market
The Global Cardiac Resynchronization Therapy (CRT) market is currently experiencing significant growth driven by the rising prevalence of cardiovascular diseases and the need for effective heart failure management. CRT-Defibrillators (CRT-D), which not only promote synchronized heart contractions but also address life-threatening arrhythmias, are becoming increasingly vital in patient treatment strategies. Innovations such as smartphone connectivity and integrated applications are enhancing patient engagement and enabling remote monitoring, further augmenting their appeal. Additionally, advancements in device design, including improved battery life and MRI compatibility, are positioning CRT-D devices as critical tools in modern cardiology, reflecting a robust upward trend in this market.